European Parliamentary Research Service (EPRS). European pharmaceutical research and development – Could public infrastructure overcome market failures? European Union, December 2021. https://www.europarl.europa.eu/RegData/etudes/STUD/2021/697197/EPRS_STU(2021)697197_EN.pdf

Uyl-de Groot CA, Heine R, Krol M, et al. Unequal access to newly registered cancer drugs leads to potential loss of life-years in Europe. Cancers. 2020;12(8):2313.

Article  PubMed  PubMed Central  Google Scholar 

Post HC, Schutte T, van Oijenet MGH, et al. Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries. ESMO Open. 2023;8(2):101208.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lawler M, Bhatti S, Przewiezlikowski P, et al. Central and Eastern Europe: A crucible for clinical cancer innovation? Journal of Cancer Policy 2025; 46:100647.

European Commission. COMBINE programme for clinical trials and medical devices endorsed by Member States, December 2024. https://ec.europa.eu/newsroom/sante/items/862110/en

European Commission. New EU rules on Health Technology Assessment open up a new era for patient access to innovation, 10 January 2025. https://ec.europa.eu/commission/presscorner/detail/en/ip_25_226

Mulder J, Teerenstra S, van Hennik PB, et al. Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit. ESMO Open. 2023;8(2):101209.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Agrawal S, Arora S, Amiri-Kordestani L, et al. Use of single-arm trials for US Food and Drug Administration drug approval in oncology, 2002–2021. JAMA Oncol. 2023;9(2):266–72.

Article  PubMed  Google Scholar 

Wang M, Ma H, Shi Y, et al. Single-arm clinical trials: design, ethics, principles. BMJ Support Palliat Care. 2024;15(1):46–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burger HU, Gerlinger C, Harbron C, et al. The use of external controls: to what extent can it currently be recommended? Pharm Stat. 2021;20(6):1002–16.

Article  PubMed  Google Scholar 

Billigham L, Brown L, Framke T, et al. Histology independent drug development - Is this the future for cancer drugs? Cancer Treat Rev. 2024;123:102674.

Article  Google Scholar 

Lewis CJ, Sarkar S, Zhu J, et al. Borrowing from historical control data in cancer drug development: a cautionary tale and practical guidelines. Stat Biopharm Res. 2019;11(1):67–78.

Article  PubMed  PubMed Central  Google Scholar 

Edwards D, Best N, Crawford J, et al. Using Bayesian dynamic borrowing to maximize the use of existing data: a case-study. Ther Innov Regul Sci. 2024;58(1):1–10.

Article  PubMed  Google Scholar 

Kessels R, May AM, Koopman M, et al. The trial within cohorts (TwiCs) study design in oncology: experience and methodological reflections. BMC Med Res Methodol. 2023. https://doi.org/10.1186/s12874-023-01941-5.

Article  PubMed  PubMed Central  Google Scholar 

Relton C, Torgerson D, O’Cathain A, et al. Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple randomised controlled trial” design. BMJ. 2010;340:c1066.

Article  PubMed  Google Scholar 

Wasmann KA, Wijsman P, van Dieren S, et al. Partially randomised patient preference trials as an alternative design to randomised controlled trials: systematic review and meta-analyses. BMJ Open. 2019;9(10):e031151.

Article  PubMed  PubMed Central  Google Scholar 

Bach SP. STAR-TREC: an international three-arm multicentre, partially randomised controlled trial incorporating an external pilot. Clin Oncol (R Coll Radiol). 2023;35(2):e107–9.

Article  CAS  PubMed  Google Scholar 

Wang Y, Li F, Blaha O, et al. Design and analysis of partially randomized preference trials with propensity score stratification. Stat Methods Med Res. 2022;31(8):1515–37.

Article  PubMed  PubMed Central  Google Scholar 

Alsop J, Scott M, Archey W. The mixed randomized trial: combining randomized, pragmatic and observational clinical trial designs. J Comp Eff Res. 2016;5(6):569–79.

Article  PubMed  Google Scholar 

Liu R, Rizzo S, Whipple S, et al. Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature. 2021;592:629–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shenoy P, Harugeri A. Elderly patients’ participation in clinical trials. Perspect Clin Res. 2015;6(4):184–9.

Article  PubMed  PubMed Central  Google Scholar 

De Rojas T, Neven A, Terada M, et al. Access to clinical trials for adolescents and young adults with cancer: a meta-research analysis. JNCI Cancer Spectr. 2019;3(4):pkz057.

Article  PubMed  PubMed Central  Google Scholar 

Gross AS, Harry AC, Clifton CS, et al. Clinical trial diversity: an opportunity for improved insight into the determinants of variability in drug response. Br J Clin Pharmacol. 2022;88(6):2700–17.

Article  PubMed  PubMed Central  Google Scholar 

World Medical Association, WMA International Code of Medical Ethics, April 2023. https://www.wma.net/policies-post/wma-international-code-of-medical-ethics/

Versavel S, Subasinghe A, Johnson K, et al. Diversity, equity, and inclusion in clinical trials: a practical guide from the perspective of a trial sponsor. Contemp Clin Trials. 2023;126:107092.

Article  PubMed  Google Scholar 

Delgado A, Guddati AK. Clinical endpoints in oncology – a primer. Am J Cancer Res. 2021;11(4):1121–31.

PubMed  PubMed Central  Google Scholar 

Cooper K, Tappenden P, Cantrell A, et al. A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer. Br J Cancer. 2020;123:1686–96.

Article  PubMed  PubMed Central  Google Scholar 

Booth CM, Eisenhauer EA, Gyawali B, et al. Progression-free survival should not be used as a primary end point for registration of anticancer drugs. J Clin Oncol. 2023;41:4968–72.

Article  PubMed  Google Scholar 

Falcone R, Lombardi P, Filetti M, et al. Oncologic drugs approval in Europe for solid tumors: overview of the last 6 years. Cancers. 2022;14(4):889.

Article  PubMed  PubMed Central  Google Scholar 

Durie B. A historic turning point: ODAC unanimously votes in favor of MRD testing as an early endpoint in myeloma clinical trials to support accelerated approvals of new treatments. International Myeloma Foundation; April 2024. https://www.myeloma.org/blog/dr-duries/odac-unanimously-in-favor-mrd-testing-early-endpoint-myeloma

Ailawadhi S, Arnulf B, Patel K, et al. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood. 2024;144(23):2389–401.

Article  CAS  PubMed  Google Scholar 

Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301–13.

Article  CAS  PubMed  Google Scholar 

Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582–96.

Article  CAS  PubMed  Google Scholar 

Mai EK, Bertsch U, Pozek E, et al. Isatuximab, lenalidomide, bortezomib, and bexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: Final part 1 analysis of the GMMG-HD7 trial. J Clin Oncol 2024:JCO2402266.

Moreau P, Dimopoulos M, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361–71.

Article  CAS  PubMed  Google Scholar 

Zabaleta A, Puig N, Cedena M, et al. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy. Am J Hematol. 2025;100(1):93–102.

Article  CAS  PubMed  Google Scholar 

Paiva B, Zherniakova A, Nuñez-Córdoba JM, et al. Impact of treatment effect on MRD and PFS: An aggregate data analysis from randomized clinical trials in multiple myeloma. Blood Adv. 2024;8(1):219–23.

Article  CAS